FDA approves Pfizer drug for rare blood cancer

Published



WASHINGTON (AP) — The Food and Drug Administration on Tuesday approved a new Pfizer drug to treat a rare form of blood and bone marrow cancer that causes a buildup of unhealthy white blood cells.

Pfizer’s Bosulif is a daily pill to treat chronic myeloid leukemia patients who carry a specific genetic variation. The disease is one of four types of the blood cancer, and accounts for about 15 percent of leukemia cases.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.